Plasma biomarkers associated with the apolipoprotein E genotype and alzheimer disease

Archives of Neurology

Volumn 69, Issue 10, 2012, Pages 1310-1317

  Soares, Holly D ^a   Potter, William Z ^c   Pickering, Eve ^b   Kuhn, Max ^b   Immermann, Frederick W ^f   Shera, David M ^g   Ferm, Mats ⁱ   Dean, Robert A ^j   Simon, Adam J ^k   Swenson, Frank ^b   Siuciak, Judith A ^c   Kaplow, June ^h   Thambisetty, Madhav ^d   Zagouras, Panayiotis ^b   Koroshetz, Walter J ^e   Wan, Hong I ^b   Trojanowski, John Q ^l   Shaw, Leslie M ^l  

^a BRISTOL MYERS SQUIBB   (United States)

^b PFIZER INC   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^f Pfizer Worldwide Research and Development   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h EISAI INC   (United States)

ⁱ ASTRAZENECA R AND D   (Sweden)

^j ELI LILLY AND COMPANY   (United States)

^k AJ Simon Enterprises LLC   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APOLIPOPROTEIN E; BIOLOGICAL MARKER; C REACTIVE PROTEIN; EOTAXIN 3; HYDROCORTISONE; IMMUNOGLOBULIN M; INTERLEUKIN 13; PANCREAS POLYPEPTIDE; TENASCIN;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E GENE; APOLIPOPROTEIN EPSILON 3 GENE; APOLIPOPROTEIN EPSILON 4 GENE; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GENE; GENOTYPE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MOLECULAR DIAGNOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; APOLIPOPROTEINS B; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHEMOKINE CXCL9; COHORT STUDIES; FEMALE; GENOTYPE; HUMANS; IMMUNOASSAY; INTERLEUKIN-3; MALE; MILD COGNITIVE IMPAIRMENT; ROC CURVE;

EID: 84867340530     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2012.1070     Document Type: Article

References (39)

1. Thies W, Bleiler L; Alzheimer's Association. 2011 Alzheimer's disease facts and figures. Alzheimers Dement. 2011;7(2):208-244.
2. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C; Medical Research Council Cognitive Function and Ageing Study. Age, neuropathology, and dementia. N Engl J Med. 2009;360(22):2302-2309.
3. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9(11):1118-1127.
4. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734-746. (Pubitemid 47058377)
5. Petersen RC, Negash S. Mild cognitive impairment: an overview. CNS Spectr. 2008;13(1):45-53. (Pubitemid 351224282)
6. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279.
7. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279.
8. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269.
9. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-292.
10. Booij BB, Lindahl T, Wetterberg P, et al. A gene expression pattern in blood for the early detection of Alzheimer's disease. J Alzheimers Dis. 2011;23(1):109-119.
11. Ewers M, Mielke MM, Hampel H. Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp Gerontol. 2010;45(1):75-79.
12. Ewers M, Walsh C, Trojanowski JQ, et al North American Alzheimer's Disease Neuroimaging Initiative (ADNI). Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging. 2012;33(7):1203-1214, e2.
13. Hye A, Lynham S, Thambisetty M, et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain. 2006;129(Pt 11):3042-3050. (Pubitemid 44684524)
14. Lovestone S, Francis P, Kloszewska I, et al; AddNeuroMed Consortium. AddNeuroMed - the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. Ann N Y Acad Sci. 2009;1180:36-46.
15. Marksteiner J, Kemmler G, Weiss EM, et al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2011;32(3):539-540.
16. Nagele E, Han M, Demarshall C, Belinka B, Nagele R. Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One. 2011;6(8):e23112. Accessed May 26, 2012.
17. O'Bryant SE, Xiao G, Barber R, et al Texas Alzheimer's Research Consortium. A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol. 2010;67(9):1077-1081.
18. Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007;13(11):1359-1362. (Pubitemid 350073592)
19. Reddy MM, Wilson R, Wilson J, et al. Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. Cell. 2011;144(1):132-142.
20. Rye PD, Booij BB, Grave G, et al. A novel blood test for the early detection of Alzheimer's disease. J Alzheimers Dis. 2011;23(1):121-129.
21. Soares HD, Chen Y, Sabbagh M, Roher A, Schrijvers E, Breteler M. Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels [published correction appears in Ann N Y Acad Sci. 2010 Feb;1188:231]. Ann N Y Acad Sci. 2009;1180:56-67.
22. Craig-Schapiro R, Kuhn M, Xiong C, et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One. 2011;6(4):e18850. Accessed May 26, 2012.
23. Hu WT, Chen-Plotkin A, Arnold SE, et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol. 2010;119(6):669-678.
24. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148(3):839-843. (Pubitemid 13033817)
25. Zhang R, Barker L, Pinchev D, et al. Mining biomarkers in human sera using proteomic tools. Proteomics. 2004;4(1):244-256. (Pubitemid 38140889)
26. Laske C, Leyhe T, Stransky E, Hoffmann N, Fallgatter AJ, Dietzsch J. Identification of a blood-based biomarker panel for classification of Alzheimer's disease. Int J Neuropsychopharmacol. 2011;14(9):1147-1155.
27. Csernansky JG, Dong H, Fagan AM, et al. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry. 2006;163(12):2164-2169. (Pubitemid 46114238)
28. Gupta VB, Laws SM, Villemagne VL, et al AIBL Research Group. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology. 2011;76(12):1091-1098.
29. Laske C, Stransky E, Fritsche A, Eschweiler GW, Leyhe T. Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia. Eur Arch Psychiatry Clin Neurosci. 2009;259(2):80-85.
30. Bruno D, Nierenberg JJ, Ritchie JC, Lutz MW, Pomara N. Cerebrospinal fluid cortisol concentrations in healthy elderly are affected by both APOE and TOMM40 variants. Psychoneuroendocrinology. 2012;37(3):366-371.
31. degli Uberti EC, Bondanelli M, Margutti A, et al. Acute administration of human galanin in normal subjects reduces the potentiating effect of pyridostigmine-induced cholinergic enhancement on release of norepinephrine and pancreatic polypeptide. Neuroendocrinology. 1996;64(5):398-404.
32. Nishikimi T, Kuwahara K, Nakao K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol. 2011;57(2):131-140.
33. Prado J, Baltrons MA, Pifarré P, García A. Glial cells as sources and targets of natriuretic peptides. Neurochem Int. 2010;57(4):367-374.
34. Kerola T, Nieminen T, Hartikainen S, Sulkava R, Vuolteenaho O, Kettunen R. B-type natriuretic peptide as a predictor of declining cognitive function and dementia - a cohort study of an elderly general population with a 5-year follow-up. Ann Med. 2010;42(3):207-215.
35. Kondziella D, Göthlin M, Fu M, Zetterberg H, Wallin A. B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia. Neuroreport. 2009;20(9):825-827.
36. Buerger K, Uspenskaya O, Hartmann O, et al. Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment. J Clin Psychiatry. 2011;72(4):556-563.
37. Riddell DR, Zhou H, Atchison K, et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci. 2008;28(45):11445-11453.
38. Kim J, Jiang H, Park S, et al. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J Neurosci. 2011;31(49):18007-18012.
39. Banwell ME, Tolley NS, Williams TJ, Mitchell TJ. Regulation of human eotaxin-3/CCL26 expression: modulation by cytokines and glucocorticoids. Cytokine. 2002;17(6):317-323.